New data from studies bolsters case for using aldosterone antagonists in heart failure
Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes and types of heart failure vary greatly, and treatment must be tailored to each patient. In some cases, doctors will prescribe a class of diuretic drugs called aldosterone antagonists. However, these diuretics may cause dangerously high levels of potassium in the blood (hyperkalemia) of certain patients, putting them at risk for sudden cardiac death. Therefore, it is crucial that doctors weigh the risks and benefits of prescribing aldosterone antagonists for their patients who have heart failure.
To help prescribers make the best decisions concerning these drugs, Bertram Pitt, MD, Professor of Internal Medicine at the University of Michigan School of Medicine, will review the data from three prominent studies during his presentation at the 7th International Symposium on Aldosterone and the ENaC/Degenerin Family of Ion Channels, being held September 18-22 in Pacific Grove, Calif. The presentation is entitled, "Potential Future Role of Mineralocorticoid Receptor Blockade in Patients with Heart Failure." The meeting is sponsored by the American Physiological Society.
Dr. Pitt will also outline a study in progress that will shed light on potential future uses of aldosterone antagonists, as well as discuss a compound currently in Phase II clinical trials that is designed to prevent or treat hyperkalemia.
EPHESUS and EMPHASIS-HF Results
Two studies for which Dr. Pitt was an investigator have shown that aldosterone antagonists reduce mortality in people with different symptoms. In 2003, the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival (EPHESUS) study demonstrated that treatment with eplerenone lowered the risk of cardiovascular mortality and cardiovascular complications 13% in people with systolic left ventricular (lower chamber) dysfunction and heart failure after a heart attack.
In 2010, the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) study revealed the drug's benefit in a broader population, i.e., patients with chronic systolic heart failure and mild symptoms. There was a 24% reduction in cardiovascular death and a 42% reduction in hospitalization for heart failure in patients who took the drug compared to those who did not.
"These results where overwhelming," Dr. Pitt said, noting that the benefits were so clear that the trials were stopped early in countries where the drug was already on the market.
The study continued for another 10 months in countries where eplerenone was not available, thus providing additional data that Dr. Pitt said reinforces the earlier findings. Furthermore, a new sub-analysis of the study showed reductions in death and hospitalization in five different groups of high-risk patients with chronic heart failure and mild symptoms, including patients older than age 75 and patients who have diabetes. Although there was an increase in the incidence of hyperkalemia among patients in the high-risk groups who took eplerenone, there was no increase in serious hyperkalemia or hyperkalemia that warranted hospitalization. Dr. Pitt will discuss the most recent data and the new sub-analysis at the meeting.
An older study, the Randomized Aldactone Evaluation Study (RALES) published in 1999, showed a benefit in people with severe heart failure and reduced left ventricular ejection fraction who took the aldosterone antagonist spironolactone. (Ejection fraction is the fraction of blood pumped out of a ventricle with each heartbeat.) "Together, these three studiesEPHESUS, EMPHASIS-HF and RALESprovide the basis for why we think aldosterone antagonists are so important," Dr. Pitt said.
Finally, Dr. Pitt will discuss the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) study, a multi-center, international trial of spironolactone that began in 2006 and is still recruiting treatment centers and enrolling participants. Patients in this study have heart failure but have not experienced disturbed function in the heart's ventricles.
Hyperkalemia Remains a Concern
Although there is substantial evidence of the benefits of aldosterone antagonists, hyperkalemia remains a concern. To that end, researchers are currently investigating a compound called RLY5016 that is designed to prevent or treat hyperkalemia by binding to potassium and pulling it out of the blood. However, the compound is only in Phase II clinical trials and will not be ready for review by the Food and Drug Administration for several years.
Dr. Pitt is cautiously hopeful. "Many of the people who are at risk for cardiovascular death, such as those with a history of diabetes or high blood pressure, are not treated with these drugs because of the risk of hyperkalemia," he said. "Ideally this compound would allow us to continue to use aldosterone antagonists in these patient groups, and in people with compromised renal and uretal function, who are at increased risk of hyperkalemia. But it is very early in the investigation and not proven by any means."
Provided by American Physiological Society
- EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation May 22, 2011 | not rated yet | 0
- USA and Europe different in aldosterone antagonists use in heart failure Oct 21, 2009 | not rated yet | 0
- The effect of eplerenone vs. placebo on cardiovascular mortality Aug 29, 2011 | not rated yet | 0
- Inexpensive drug can reduce deaths from heart failure, study finds Nov 16, 2010 | not rated yet | 0
- Recommended treatment for heart failure often underused Oct 20, 2009 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Electric field-Charge inside a metallic shell
1 hour ago I am having few doubts while studying electric field which i am putting here Suppose there is a spherical metallic shell with point charge q1 at...
Change in momentum when a body is thrown up and falls back down.
8 hours ago Say, a body of mass 'm' is thrown at a certain angle with the vertical with certain initial velocity 'u'. The initial momentum of this object is mu....
change in speed and wavelength of light while travelling from one med
8 hours ago what is the mechanism by which light changes its speed and wavelength while travelling from one medium to other. I know it is c/n or lamda/n and know...
Calculus of Variation - Classical Mechanics
11 hours ago I'm reading Classical Mechanics (Taylor), and the 6th chapter is a basic introduction to calculus of variations. I'm super confused :confused: ...
Frictional Force Equation Doesn't Make Sense
11 hours ago Frictional Force is mathematically defined as: Ff = μ*m*g*cos(θ) , where μ is the coefficient of friction, m is the mass of the object, g is...
Calculating Steam Pressure in Closed Container
16 hours ago I am trying to calculate the volume of liquid water i need to place in a sealed container in order to obtain 10 psi of steam pressure in that closed...
- More from Physics Forums - Classical Physics
More news stories
(HealthDay)—Blood levels of free fatty acids are associated with insulin resistance during young adulthood and cardiovascular risk factors in later adulthood, according to a study published online May 13 ...
Cardiology May 17, 2013 | not rated yet | 0 |
An experimental, inexpensive iPhone application transmitted diagnostic heart images faster and more reliably than emailing photo images, according to a research study presented at the American Heart Association's Quality ...
Cardiology May 17, 2013 | not rated yet | 0
Extracorporeal membrane oxygenation (ECMO), a procedure traditionally used during cardiac surgeries and in the ICU that functions as an artificial replacement for a patient's heart and lungs, has also been used to resuscitate ...
Cardiology May 17, 2013 | not rated yet | 0
Age has little to do with how patients should be treated after suffering a stroke, according to new research from the University of Georgia.
Cardiology May 17, 2013 | not rated yet | 0 |
Depressed middle-aged women have almost double the risk of having a stroke, according to research published in Stroke: Journal of the American Heart Association.
Cardiology May 16, 2013 | not rated yet | 0
The devastating effect of Alzheimer's disease on bilingual people has been thrown into focus in Canada, where the sudden loss of a second language can leave sufferers feeling like strangers in their own country.
1 hour ago | not rated yet | 0
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
3 hours ago | not rated yet | 0
Regular consumption of coffee is associated with a reduced risk of primary sclerosing cholangitis (PSC), an autoimmune liver disease, Mayo Clinic research shows. The findings were being presented at the Digestive Disease ...
11 hours ago | not rated yet | 0 |
Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the ...
11 hours ago | 4.7 / 5 (3) | 0 |
Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.
10 hours ago | not rated yet | 1
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
10 hours ago | not rated yet | 0